'Fast Money' Recap: What Market? The Focus Remains on Apple
at The Street - 1 hr ago
The trading panel discussed how low the market can go and whether biotech stocks can continue to move higher.
Jim Cramer's 'Mad Money' Recap: Why You Can't Get Too Negative in This Market
at The Street - Wed Sep 24, 7:24PM CDT
Investors always need to be prepared for when common sense returns to the market, Cramer says.
Gilead reports good HIV trial
at Investor's Business Daily - Wed Sep 24, 5:30PM CDT
The biotech reported good late-stage trial data for its new HIV drug. The trial compared a standard combination of drugs in Gilead's (GILD) Stribild to a trial in which 1 of the components, sold individually as Viread, was replaced with tenofovir...
Novavax's Influenza Vaccine Study Shows Adjuvant Efficiency - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 5:10PM CDT
Novavax, Inc. (NVAX) announced positive top-line data from a phase I/II study on influenza vaccine candidate, H7N9 VLP.
Final Glance: Biotechnology companies
AP - Wed Sep 24, 5:03PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Gilead (GILD) Seeks Japanese Approval for HCV Combo Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 5:00PM CDT
Gilead (GILD) is seeking Japanese approval for the combination of Sovaldi and ledipasvir .
Celgene's Otezla Label Expanded to Include Plaque Psoriasis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 4:30PM CDT
Celgene's (CELG) Otezla gained FDA approval for plaque psoriasis.
Emergent BioSolutions Initiates Pivotal Study on BioThrax - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 4:20PM CDT
Emergent BioSolutions (EBS) initiated a pivotal non-clinical study on BioThrax to support the licensure of the company's new modern facility, Building 55.
Watch for Gilead Sciences to Potentially Pullback After Gaining 3.10% Yesterday
Comtex SmarTrend(R) - Wed Sep 24, 3:37PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $106.02 to a high of $108.81. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $107.89 on volume of 14.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
After Yesterday's Rally of 3.10% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Sep 24, 3:37PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $106.02 to a high of $108.81. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $107.89 on volume of 14.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Gilead's Next-Gen HIV Drug Bests Stribild In Trials
at Investor's Business Daily - Wed Sep 24, 12:39PM CDT
Big-cap biotech and IBD 50 stock Gilead Sciences (GILD) reported good late-stage trial data for its new HIV drug Wednesday. Analysts nicknamed the drug "son of Viread" and expect it to be a blockbuster. The stock was up about 2.2% by afternoon...
Acorda To Buy Civitas, Gains Parkinson's Disease Drug
at Investor's Business Daily - Wed Sep 24, 12:27PM CDT
Acorda Therapeutics (ACOR) stock popped after the biotechnology company agreed to buy privately held Civitas Therapeutics for $525 million, gaining access to drugs in late development used to treat Parkinson's disease. Acorda obtained global rights...
Midday Glance: Biotechnology companies
AP - Wed Sep 24, 12:21PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Early Glance: Biotechnology companies
AP - Wed Sep 24, 9:33AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Critical Alerts For Gilead Sciences, Ambarella, American Capital Agency, NetApp and Ford Released By InvestorsObserver
PR Newswire - Wed Sep 24, 9:33AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GILD, AMBA, AGNC, NTAP and F.
Gilead Sciences' Next-Generation HIV Drug Hits the Mark
at The Street - Wed Sep 24, 9:30AM CDT
TAF is an improved version of Gilead's stalwart but patent challenged HIV drug Viread.
Acceleron Pharma (XLRN) Jumps: Stock Rises 12.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 8:39AM CDT
Acceleron Pharma (XLRN) was a big mover last session, as its shares rose almost 13% on the day.
Sangamo Biosciences (SGMO) Jumps: Stock Rises 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 7:51AM CDT
Sangamo Biosciences Inc. (SGMO) was a big mover last session, as its shares rose over 5% on the day.
The Next Blue Chip Stocks: Gilead Sciences, Inc.
Todd Campbell, The Motley Fool - Motley Fool - Wed Sep 24, 7:35AM CDT
Source: Gilead Sciences via Google Maps Great blue chip stocks aren't made overnight and they're rarely content playing second fiddle in their market. Instead, they're established leaders that dominate their competition. By that definition,...